



**A Birtle**

**Kontakt**

A Birtle

## Publikationen (5)

STAMPEDE Investigators, Parikh O, O'Sullivan J, Omlin A, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Protheroe A, Rudman S, Srihari N, James N, Parmar M, Sydes M, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J, Simms M, Brown J, Russell J, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C, Attard G, Amos C, Hoyle A, Ingleby F, Ali A, Dearnaley D, Douis H, Gilbert D, Ritchie A, Parker C, Millman R, Matheson D, Mason M, Malik Z, MacNair A, Langley R, Jones R, Gillessen S, Clarke N. Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: *Ann Oncol* 2019; 30: 1992-2003. *Ann Oncol* 2020; 31:442.

Khoo V, N'Dow J, Necchi A, Neuzillet Y, Oddens J, Oldenburg J, Osanto S, Oyen W, Pacheco-Figueiredo L, Pappot H, Patel M, Pieters B, Plass K, Remzi M, Müller C, Müller A, Kiltie A, Krege S, Ladoire S, Lara P, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Carmen Mir M, Moschini M, Mostafid H, Retz M, Richenberg J, Turkbey B, Vahr Lauridsen S, Valdagni R, Van Der Heijden A, Van Poppel H, Vartolomei M, Veskimäe E, Vilaseca A, Vives Rivera F, Wiegel T, Wiklund P, Williams A, Zigeuner R, Tombal B, Thalmann G, Rink M, Roghmann F, Rosenberg J, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk R, Smits A, Stenzl A, Witjes J, Kamat A, Horwich A, Arends T, Bamias A, Birtle A, Black P, Bochner B, Bolla M, Boormans J, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Agarwal N, Xylinas E, Babjuk M, Bellmunt J, Bruins H, De Reijke T, De Santis M, Gillessen Sommer S, James N, Maclennan S, Palou J, Powles T, Ribal M, Shariat S, van der Kwast T, Chiti A, Choudhury A, Gontero P, Grubmüller B, Hafeez S, Hansel D, Hartmann A, Hayne D, Henry A, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jerezcek-Fossa B, Geavlete B, Gakis G, Compérat E, Crabb S, Culine S, De Bari B, DeBlok W, De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig J, Fanti S, Fonteyne V, Frydenberg M, Futterer J, Jones R. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. *Ann Oncol* 2020; 30:1697-1727.

Khoo V, N'Dow J, Necchi A, Neuzillet Y, Oddens J, Oldenburg J, Osanto S, Oyen W, Pacheco-Figueiredo L, Pappot H, Patel M, Pieters B, Plass K, Remzi M, Müller C, Müller A, Kiltie A, Krege S, Ladoire S, Lara P, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir M, Moschini M, Mostafid H, Retz M, Richenberg J, Turkbey B, Lauridsen S, Valdagni R, Van Der Heijden A, Van Poppel H, Vartolomei M, Veskimäe E, Vilaseca A, Rivera F, Wiegel T, Wiklund P, Williams A, Zigeuner R, Tombal B, Thalmann G, Rink M, Roghmann F, Rosenberg J, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk R, Smits A, Stenzl A, Witjes J, Kamat A, Horwich A, Arends T, Bamias A, Birtle A, Black P, Bochner B, Bolla M, Boormans J, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Agarwal N, Xylinas E, Babjuk M, Bellmunt J, Bruins H, Reijke T, Santis M, Gillessen Sommer S, James N, Maclennan S, Palou J, Powles T, Ribal M, Shariat S, Kwast T, Chiti A, Choudhury A, Gontero P, Grubmüller B, Hafeez S, Hansel D, Hartmann A, Hayne D, Henry A, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jerezcek-Fossa B, Geavlete B, Gakis G, Compérat E, Crabb S, Culine S, Bari B, Blok W, De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig J, Fanti S, Fonteyne V, Frydenberg M, Futterer J, Jones R. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. *Ann Oncol* 2019; 30:1697-1727.

James N, O'Sullivan J, Omlin A, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Brown J, Parikh O, Protheroe A, Rudman S, Parmar M, Sydes M, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J, Simms M, Srihari N, Russell J, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C, Attard G, Amos C, Hoyle A, Ingleby F, Ali A, Dearnaley D, Douis H, Gilbert D, Ritchie A, Parker C, Millman R, Matheson D, Mason M, Malik Z, MacNair A, Langley R, Jones R, Gillessen S, Clarke N. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. *Ann Oncol* 2019

STAMPEDE Investigators, Protheroe A, Peedell C, Parikh O, O'Sullivan J, Nikapota A, Lester J, McLaren D, Hughes R, Gilbert D, Gibbs S, Rudman S, Shaffer R, Sheehan D, James N, Parmar M, Wagstaff J, Varughese M, Tsang D, Tolan S, Sundar S, Strebel R, Srihari N, Simms M, Gale J, Ford D, Evans L, Malik Z, Gillessen Sommer S, Cross W, Chowdhury S, Attard G, de Bono J, Dearnaley D, Clarke N, Mason M, Spears M, Jones R, Parker C, Ritchie A, Choudhury A, Chakraborti P, Capaldi L, Brock S, Birtle A, Gilson C, Amos C, Matheson D, Millman R, Russell J, Sydes M. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. *Ann Oncol* 2018; 29:1235-1248.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)